Rin Nagaoka
About
In The Last Decade
Rin Nagaoka
13 papers receiving 181 citations
Peers
Comparison fields: 5 of 47
- Oncology 74
- Cancer Research 67
- Surgery 45
- Endocrinology, Diabetes and Metabolism 33
- Radiology, Nuclear Medicine and Imaging 32
Countries citing papers authored by Rin Nagaoka
This map shows the geographic impact of Rin Nagaoka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rin Nagaoka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rin Nagaoka more than expected).
Fields of papers citing papers by Rin Nagaoka
This network shows the impact of papers produced by Rin Nagaoka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rin Nagaoka. The network helps show where Rin Nagaoka may publish in the future.
Co-authorship network of co-authors of Rin Nagaoka
This figure shows the co-authorship network connecting the top 25 collaborators of Rin Nagaoka. A scholar is included among the top collaborators of Rin Nagaoka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rin Nagaoka. Rin Nagaoka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 33 | |
| 2 | 26 | |
| 3 | Clinicopathological Features of Cases with Primary Breast Cancer not Identified by 18F-FDG-PET. | 7 |
| 4 | 2 | |
| 5 | 0 | |
| 6 | 0 | |
| 7 | 7 | |
| 8 | Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a single-institute experience. | 7 |
| 9 | 24 | |
| 10 | 10 | |
| 11 | Neoadjuvant weekly paclitaxel with and without trastuzumab in locally advanced or metastatic breast cancer. | 14 |
| 12 | 8 | |
| 13 | 0 | |
| 14 | 26 | |
| 15 | 7 | |
| 16 | Local control by breast-conserving surgery with nipple resection. | 13 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.